These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21850490)

  • 61. Protective and restorative effects of magnolol on neurotoxicity in mice with 6-hydroxydopamine-induced hemiparkinsonism.
    Chen HH; Lin SC; Chan MH
    Neurodegener Dis; 2011; 8(5):364-74. PubMed ID: 21494012
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism.
    Roghani M; Niknam A; Jalali-Nadoushan MR; Kiasalari Z; Khalili M; Baluchnejadmojarad T
    Brain Res Bull; 2010 Jul; 82(5-6):279-83. PubMed ID: 20558255
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase.
    Mori MA; Delattre AM; Carabelli B; Pudell C; Bortolanza M; Staziaki PV; Visentainer JV; Montanher PF; Del Bel EA; Ferraz AC
    Nutr Neurosci; 2018 Jun; 21(5):341-351. PubMed ID: 28221817
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of bromelain on motor responses following intra-medial forebrain bundle 6-OHDA injection in rat model of parkinsonism.
    Adu TS; Mabandla MV
    Metab Brain Dis; 2019 Dec; 34(6):1557-1564. PubMed ID: 31332728
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Neuroprotection by scorpion venom heat resistant peptide in 6-hydroxydopamine rat model of early-stage Parkinson's disease.
    Yin SM; Zhao D; Yu DQ; Li SL; An D; Peng Y; Xu H; Sun YP; Wang DM; Zhao J; Zhang WQ
    Sheng Li Xue Bao; 2014 Dec; 66(6):658-66. PubMed ID: 25516514
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson's disease.
    Liang Q; Smith AD; Pan S; Tyurin VA; Kagan VE; Hastings TG; Schor NF
    Biochem Pharmacol; 2005 Nov; 70(9):1371-81. PubMed ID: 16144694
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunohistochemical changes of nigrostriatal tyrosine hydroxylase and dopamine transporter in the golden hamster after a single intrastriatal injection of 6-hydroxydopamine.
    Rodríguez S; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 May; 65(4):463-8. PubMed ID: 22357095
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Attenuation by Nardostachys jatamansi of 6-hydroxydopamine-induced parkinsonism in rats: behavioral, neurochemical, and immunohistochemical studies.
    Ahmad M; Yousuf S; Khan MB; Hoda MN; Ahmad AS; Ansari MA; Ishrat T; Agrawal AK; Islam F
    Pharmacol Biochem Behav; 2006 Jan; 83(1):150-60. PubMed ID: 16500697
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat.
    Ambrosi G; Kustrimovic N; Siani F; Rasini E; Cerri S; Ghezzi C; Dicorato G; Caputo S; Marino F; Cosentino M; Blandini F
    Neurotox Res; 2017 Jul; 32(1):71-81. PubMed ID: 28285346
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
    Borah A; Mohanakumar KP
    Brain Res; 2010 Jul; 1344():192-9. PubMed ID: 20470760
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A bibenzyl compound 20C protects rats against 6-OHDA-induced damage by regulating adaptive immunity associated molecules.
    Wang S; Han QW; Zhou TT; Zhang CL; Zhu CG; Zhou X; Chen NH; Yuan YH; Shi JG
    Int Immunopharmacol; 2021 Feb; 91():107269. PubMed ID: 33340781
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Neuronal activity in the medial associative-limbic and lateral motor part of the rat subthalamic nucleus and the effect of 6-hydroxydopamine-induced lesions of the dorsolateral striatum.
    Lindemann C; Alam M; Krauss JK; Schwabe K
    J Comp Neurol; 2013 Oct; 521(14):3226-40. PubMed ID: 23787707
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Neural metabolite changes in corpus striatum after rat multipotent mesenchymal stem cells transplanted in hemiparkinsonian rats by magnetic resonance spectroscopy.
    Fu W; Zheng Z; Zhuang W; Chen D; Wang X; Sun X; Wang X
    Int J Neurosci; 2013 Dec; 123(12):883-91. PubMed ID: 23768098
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Changes in surface expression of N-methyl-D-aspartate receptors in the striatum in a rat model of Parkinson's disease.
    Gan J; Qi C; Mao LM; Liu Z
    Drug Des Devel Ther; 2014; 8():165-73. PubMed ID: 24465126
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Perillyl Alcohol Mitigates Behavioural Changes and Limits Cell Death and Mitochondrial Changes in Unilateral 6-OHDA Lesion Model of Parkinson's Disease Through Alleviation of Oxidative Stress.
    Anis E; Zafeer MF; Firdaus F; Islam SN; Khan AA; Hossain MM
    Neurotox Res; 2020 Aug; 38(2):461-477. PubMed ID: 32394056
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neuroprotective Effects of Ellagic Acid in a Rat Model of Parkinson's Disease.
    Sarkaki A; Farbood Y; Dolatshahi M; Mansouri SM; Khodadadi A
    Acta Med Iran; 2016 Aug; 54(8):494-502. PubMed ID: 27701719
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study.
    Boulamery A; Simon N; Vidal J; Bruguerolle B
    Chronobiol Int; 2010 Jan; 27(2):251-64. PubMed ID: 20370468
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.